DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers

Naotaka Izuo; Hajime Miyanishi; Daisuke Nishizawa; Takuma Fujii; Junko Hasegawa; Naomi Sato; Fumihiko Tanioka; Haruhiko Sugimura; Kazutaka Ikeda; Atsumi Nitta

doi:10.1002/npr2.12373

DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers

Naotaka Izuo, Hajime Miyanishi, Daisuke Nishizawa, Takuma Fujii, Junko Hasegawa, Naomi Sato, Fumihiko Tanioka, Haruhiko Sugimura, Kazutaka Ikeda, Atsumi Nitta^*

^*Corresponding author for this work

Pharmaceutical Therapy and Neuropharmacology

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: Cigarette smoking is a preventable risk factor for various diseases such as cancer, ischemic stroke, cardiac stroke, and chronic obstructive pulmonary disease. Smoking cessation is of great importance not only for individual smokers but also for social health. Regarding current cessation therapies, the effectiveness of nicotine replacement is limited, and the cost of varenicline medication is considerable. Thus, a method for screening smokers who are responsive to cessation therapy based on the therapeutic effectiveness is required. Peripheral biomarkers reflecting smoking dependence status are necessary to establish a method for achieving effective cessation therapy. Methods: Methylation status of smokers' blood DNA was evaluated focusing on SHATI/NAT8L, an addiction-related gene. Eight CpG sites in SHATI/NAT8L were quantified by pyrosequencing. Results: There was no difference in the methylation status of this gene between smokers (n = 129) and non-smokers (n = 129) at all CpG sites. No correlations between the methylation status of SHATI/NAT8L and indicators of smoking dependence were found. Conclusions: Although the present study found no significance in the DNA methylation of SHATI/NAT8L among smokers, the exploration of predictable peripheral biomarkers for the effectiveness of smoking cessation therapy is required.

Original language	English
Pages (from-to)	570-575
Number of pages	6
Journal	Neuropsychopharmacology Reports
Volume	43
Issue number	4
DOIs	https://doi.org/10.1002/npr2.12373
State	Published - 2023/12

Keywords

DNA methylation
SHATI/NAT8L
cigarette smoker
pyrosequencing
tobacco dependence screener

ASJC Scopus subject areas

Clinical Psychology
Pharmacology
Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/npr2.12373

Cite this

@article{fe79484cce9c47818d855d3ef970762f,

title = "DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers",

abstract = "Aims: Cigarette smoking is a preventable risk factor for various diseases such as cancer, ischemic stroke, cardiac stroke, and chronic obstructive pulmonary disease. Smoking cessation is of great importance not only for individual smokers but also for social health. Regarding current cessation therapies, the effectiveness of nicotine replacement is limited, and the cost of varenicline medication is considerable. Thus, a method for screening smokers who are responsive to cessation therapy based on the therapeutic effectiveness is required. Peripheral biomarkers reflecting smoking dependence status are necessary to establish a method for achieving effective cessation therapy. Methods: Methylation status of smokers' blood DNA was evaluated focusing on SHATI/NAT8L, an addiction-related gene. Eight CpG sites in SHATI/NAT8L were quantified by pyrosequencing. Results: There was no difference in the methylation status of this gene between smokers (n = 129) and non-smokers (n = 129) at all CpG sites. No correlations between the methylation status of SHATI/NAT8L and indicators of smoking dependence were found. Conclusions: Although the present study found no significance in the DNA methylation of SHATI/NAT8L among smokers, the exploration of predictable peripheral biomarkers for the effectiveness of smoking cessation therapy is required.",

keywords = "DNA methylation, SHATI/NAT8L, cigarette smoker, pyrosequencing, tobacco dependence screener",

author = "Naotaka Izuo and Hajime Miyanishi and Daisuke Nishizawa and Takuma Fujii and Junko Hasegawa and Naomi Sato and Fumihiko Tanioka and Haruhiko Sugimura and Kazutaka Ikeda and Atsumi Nitta",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.",

year = "2023",

month = dec,

doi = "10.1002/npr2.12373",

language = "英語",

volume = "43",

pages = "570--575",

journal = "Neuropsychopharmacology Reports",

issn = "2574-173X",

publisher = "John Wiley & Sons Inc.",

number = "4",

}

TY - JOUR

T1 - DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers

AU - Izuo, Naotaka

AU - Miyanishi, Hajime

AU - Nishizawa, Daisuke

AU - Fujii, Takuma

AU - Hasegawa, Junko

AU - Sato, Naomi

AU - Tanioka, Fumihiko

AU - Sugimura, Haruhiko

AU - Ikeda, Kazutaka

AU - Nitta, Atsumi

PY - 2023/12

Y1 - 2023/12

N2 - Aims: Cigarette smoking is a preventable risk factor for various diseases such as cancer, ischemic stroke, cardiac stroke, and chronic obstructive pulmonary disease. Smoking cessation is of great importance not only for individual smokers but also for social health. Regarding current cessation therapies, the effectiveness of nicotine replacement is limited, and the cost of varenicline medication is considerable. Thus, a method for screening smokers who are responsive to cessation therapy based on the therapeutic effectiveness is required. Peripheral biomarkers reflecting smoking dependence status are necessary to establish a method for achieving effective cessation therapy. Methods: Methylation status of smokers' blood DNA was evaluated focusing on SHATI/NAT8L, an addiction-related gene. Eight CpG sites in SHATI/NAT8L were quantified by pyrosequencing. Results: There was no difference in the methylation status of this gene between smokers (n = 129) and non-smokers (n = 129) at all CpG sites. No correlations between the methylation status of SHATI/NAT8L and indicators of smoking dependence were found. Conclusions: Although the present study found no significance in the DNA methylation of SHATI/NAT8L among smokers, the exploration of predictable peripheral biomarkers for the effectiveness of smoking cessation therapy is required.

AB - Aims: Cigarette smoking is a preventable risk factor for various diseases such as cancer, ischemic stroke, cardiac stroke, and chronic obstructive pulmonary disease. Smoking cessation is of great importance not only for individual smokers but also for social health. Regarding current cessation therapies, the effectiveness of nicotine replacement is limited, and the cost of varenicline medication is considerable. Thus, a method for screening smokers who are responsive to cessation therapy based on the therapeutic effectiveness is required. Peripheral biomarkers reflecting smoking dependence status are necessary to establish a method for achieving effective cessation therapy. Methods: Methylation status of smokers' blood DNA was evaluated focusing on SHATI/NAT8L, an addiction-related gene. Eight CpG sites in SHATI/NAT8L were quantified by pyrosequencing. Results: There was no difference in the methylation status of this gene between smokers (n = 129) and non-smokers (n = 129) at all CpG sites. No correlations between the methylation status of SHATI/NAT8L and indicators of smoking dependence were found. Conclusions: Although the present study found no significance in the DNA methylation of SHATI/NAT8L among smokers, the exploration of predictable peripheral biomarkers for the effectiveness of smoking cessation therapy is required.

KW - DNA methylation

KW - SHATI/NAT8L

KW - cigarette smoker

KW - pyrosequencing

KW - tobacco dependence screener

UR - http://www.scopus.com/inward/record.url?scp=85169812004&partnerID=8YFLogxK

U2 - 10.1002/npr2.12373

DO - 10.1002/npr2.12373

M3 - 学術論文

C2 - 37668111

AN - SCOPUS:85169812004

SN - 2574-173X

VL - 43

SP - 570

EP - 575

JO - Neuropsychopharmacology Reports

JF - Neuropsychopharmacology Reports

IS - 4

ER -

DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this